IGF synergy in cancer

Why Boehringer, Lilly are combining an IGF and CDK4/6 inhibitor in breast cancer

Despite a history of failures in targeting the insulin-like growth factor receptor for cancer, Boehringer Ingelheim GmbH and Eli Lilly and Co. have several hypotheses that support greater cell cycle arrest and the potential to disrupt resistance mechanisms when both cyclin dependent kinase 4 and the IGF pathway are inhibited in metastatic breast cancer.

The companies plan to test these theories in a collaboration that will include mechanistic preclinical studies and a Phase Ib combination trial of Lilly's CDK4/6 inhibitor abemaciclib and Boehringer's BI 836845, a human mAb that binds to IGF-1 and IGF-2.

The literature broadly outlines the role of the IGF

Read the full 1042 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE